Interplay between polygenic effects and polypharmacy on dementia: An investigation in an elderly Scottish cohort.

Vasilis Raptis,Donncha Mullin,Sumbul Syed,Ian J Deary,Simon R Cox,Tom C Russ,Michelle Luciano
DOI: https://doi.org/10.1101/2024.11.01.24316584
2024-11-02
Abstract:INTRODUCTION: Polygenic Risk Scores for Alzheimer dementia (AD-PRS), a measure of aggregate AD genetic risk and polypharmacy have been associated with dementia. Here, we test their interaction's association with future dementia among older adults without baseline neurodegenerative diagnoses. METHODS: Using Cox proportional hazards and mortality-adjusted competing risk regression models we analysed up to 17.5 years all-cause incident dementia in the Lothian Birth Cohort 1936 (n=759, 105 dementia patients). We used polypharmacy (total or nervous-system-acting medications count), AD-PRS, and their interaction as main predictors. RESULTS: A non-significant interaction was found between AD-PRS and total polypharmacy (HR=1.06; p=0.15) or nervous-system-acting polypharmacy (HR=0.98; p=0.86) in shaping dementia risk. Omitting interaction, mortality-adjusted models showed significant AD-PRS prediction of dementia (HR ~1.40; p<0.001), non-significant total (HR=1.03; p=0.49), and nervous-system-acting polypharmacy effects (HR=1.27; p=0.069). DISCUSSION: Elucidating the complex interplay between polypharmacy and genetics could improve management of inappropriate medication in older adults genetically prone to dementia/AD.
What problem does this paper attempt to address?